JRCT ID: jRCTs041190040
Registered date:10/06/2019
RCT of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Pncreatic cancer |
| Date of first enrollment | 15/12/2017 |
| Target sample size | 56 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | TJ-3020 |
Outcome(s)
| Primary Outcome | Assessment of fatigue and Malaise |
|---|---|
| Secondary Outcome | Assessment of QOL, Assesment of pain, Relative dose intensity |
Key inclusion & exclusion criteria
| Age minimum | >= 20age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | Unresectable or relapse pancreatic cancer |
| Exclude criteria | Herbal medicine Allergies |
Related Information
| Primary Sponsor | Takami Hideki |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Hideki Takami |
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya, Japan Aichi Japan 466-8550 |
| Telephone | +81-52-744-2249 |
| takamihideki@med.nagoya-u.ac.jp | |
| Affiliation | Nagoya University Graduate School of Medicine |
| Scientific contact | |
| Name | Hideki Takami |
| Address | 65 Tsurumai-cho, Showa-ku, Nagoya, Japan Aichi Japan 466-8550 |
| Telephone | +81-52-744-2249 |
| takamihideki@med.nagoya-u.ac.jp | |
| Affiliation | Nagoya University Graduate School of Medicine |